Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical ...

Weight-loss meds go head-to-head in new study. One was significantly more effective, drugmaker says - In the first ...

W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

Eli Lilly's Zepbound has outperformed Novo Nordisk's Wegovy in a pivotal clinical trial, marking a significant milestone in ...

People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...

Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in ...

Novo Nordisk, the Danish company that makes diabetes drug Ozempic and obesity treatment Wegovy, has begun work on a 5.3ha ...

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...